Northsea_Segovia (Intestinal Failure-Associated Liver Disease) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called NST-6179 (the study drug) is a a safe and effective option for patients with intestinal failure-associated liver disease (IFALD).
Intestinal Failure-Associated Liver Disease (IFALD)
Who Can Participate in the Study?
Adults ages 18+ who:
- Have liver disease that is associated with intestinal failure
- Do not have liver failure
- Have been getting parenteral nutrition (through a catheter) for at least 6 months
- Have not had intestinal surgery for at least 3 months
- Do not need a feeding tube to take medicine
For more information about this study, contact the study team at christy.walters@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (by chance) to get the study drug or a placebo (inactive substance with no drug in it). You will have a 2-in-3 chance of getting the study drug. The study drug and placebo are a liquid solution that you take by mouth once per day.
You will visit our clinic every 2 weeks while you are in the study. The study will last for about 10 weeks.
Study Details
